Acumen Pharmaceuticals, Inc. - Common Stock (ABOS)
1.2392
+0.0292 (2.41%)
Acumen Pharmaceuticals Inc is a biotechnology company focused on developing innovative therapeutics aimed at treating neurodegenerative diseases, particularly Alzheimer's disease
The company's research emphasizes the creation of targeted treatments that aim to modify disease progression and improve cognitive function in patients. Acumen leverages advanced scientific methodologies to explore novel mechanisms of action, striving to bring meaningful advancements to the field of neurology and enhance the quality of life for those affected by these challenging conditions.
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a broader market where technology rules.
Longeveron (NASDAQLGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™ cellular drug in the next 3 to 4 months.
Gainers Biophytis S.A. (NASDAQBPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's main product.
